Danny Mounir, MD
Obstetrics & Gynecology · Webster, TXNPI 1508286634
Payments from drug & device makers
Across 89 payments — averaging $47.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Medtronic$670
- Astellas Pharma US Inc$500
- Coloplast$455
- Femselect Inc.$250
- Coopersurgical, Inc.$181
- plus $1K from 25 others
What the payments were for
- Grants$3568%
- Food & beverage$3,36579%
- Education$52212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 11 | $1,084 |
| Medtronic(2 entities) | 16 | $670 |
| Astellas Pharma US Inc | 11 | $500 |
| Coloplast | 10 | $455 |
| Femselect Inc. | 2 | $250 |
| Coopersurgical, Inc. | 3 | $181 |
| Urovant Sciences Inc | 2 | $146 |
| Axonics, Inc. | 4 | $128 |
| Caldera Medical, Inc | 2 | $90 |
| AbbVie | 3 | $75 |
| Tesaro, Inc. | 2 | $70 |
| Mayne Pharma Commercial LLC | 2 | $66 |
| Davol Inc. | 1 | $61 |
| Sumitomo Pharma America, Inc. | 2 | $51 |
| Intuitive Surgical | 1 | $48 |
| Ambu Inc. | 1 | $34 |
| Baxter Healthcare | 1 | $33 |
| Pharmacosmos Therapeutics Inc. | 1 | $30 |
| Johnson & Johnson(2 entities) | 2 | $30 |
| Pacira Pharmaceuticals Incorporated | 1 | $28 |
| Bayer | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| KCI USA, Inc. | 1 | $22 |
| Exeltis, USA Inc. | 1 | $21 |
| Evofem Biosciences, Inc. | 1 | $18 |
| Bioventus LLC | 1 | $17 |
| Dentsply IH Inc. | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Convatec Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL FEMALE SUI$657
- GENERAL PELVIC ORGAN PROLAPSE$356
- EnPlace$231
- INTERSTIM$132
- GEMTESA$125
- Advincula Delineator Uterine Manipulator$121
- V-LOC 180$109
- TITAN$104
How this compares
$4,243 in reported general payments places this provider in the 80th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 167 | $145,006 |
| MyrbetriqMirabegron | 119 | $81,224 |
| Estradiol | 486 | $29,629 |
| BotoxOnabotulinumtoxina | 22 | $17,990 |
| Mirabegron ErMirabegron | 25 | $16,394 |
| Trospium Chloride ErTrospium Chloride | 74 | $10,097 |
| Trospium Chloride | 57 | $3,098 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 159 | $2,299 |
| Solifenacin Succinate | 41 | $2,232 |
| Clobetasol Propionate | 44 | $1,946 |
| Fosfomycin Tromethamine | 16 | $1,916 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $1,576 |
| Tamsulosin Hcl | 104 | $1,007 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 115 | $804 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 30 | $559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $51 | $145,006167 claims |
| Astellas Pharma US IncMyrbetriq | $500 | $81,224119 claims |
| AbbVieBotox | $75 | $17,99022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,099 obstetrics & gynecology providers in Texas.
Other obstetrics & gynecology in Webster
- Catherine HansenWebster$357K
- Amir JazaeriHouston$19.5M
- Shannon WestinHouston$17.3M
- Monica LopezFort Worth$8.1M
- Cynthia RobbinsFort Worth$7.8M
- John Paul RobertsPlano$4.9M
- Stephen StamatisWeatherford$4.5M
- Parke HedgesSan Antonio$4.2M
- Mary MartinBeaumont$2.8M
- Mark JacobsHouston$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.